
Regenxbio Showcases RGX-121 at the 21st Annual World Symposium: Groundbreaking Gene Therapy Advancements
REGENXBIO’s MPS II Treatment Data to be Presented at WORLDSymposium™ 2025 REGENXBIO Inc., a leading clinical-stage biotechnology company focused on developing and commercializing gene therapy products for patients with rare genetic diseases, recently made an exciting announcement. The company will be sharing data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of Mucopolysaccharidosis type…